Comment on: Safinamide as adjunctive therapy for Parkinson's disease: A promising option with room for improvement

被引：0
|
作者：
Matovu, Daniel [1 ]
机构：
[1] Kabale Univ, Dept Clin Pharmacol & Therapeut, Kabale, Uganda
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2024年 / 462卷
关键词：
MAO-B inhibitor; Wearing-off; Parkinson's disease; Safinamide;
D O I：
10.1016/j.jns.2024.123103
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Fatigue in fluctuating Parkinson's disease patients: possible impact of safinamide
    Pauletti, Caterina
    Locuratolo, Nicoletta
    Mannarelli, Daniela
    Maffucci, Andrea
    Petritis, Alessia
    Menini, Elisa
    Fattapposta, Francesco
    JOURNAL OF NEURAL TRANSMISSION, 2023, 130 (07) : 915 - 923
  • [32] Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
    Loprete, Luca
    Leuratti, Chiara
    Cattaneo, Carlo
    Thapar, Mita M.
    Farrell, Colm
    Sardina, Marco
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (05):
  • [33] Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease
    Schapira, A. H. V.
    Stocchi, F.
    Borgohain, R.
    Onofrj, M.
    Bhatt, M.
    Lorenzana, P.
    Lucini, V.
    Giuliani, R.
    Anand, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (02) : 271 - 280
  • [34] Real-world use of Safinamide in motor fluctuating Parkinson’s disease patients in Italy
    Roberta Bovenzi
    Claudio Liguori
    Margherita Canesi
    Marco D’Amelio
    Maria Francesca De Pandis
    Carmine Marini
    Alessandra Monge
    Alessandro Padovani
    Alessandro Tessitore
    Alessandro Stefani
    Mario Zappia
    Neurological Sciences, 2024, 45 : 573 - 583
  • [35] Long-Term Real-World Experience with Safinamide in Patients with Parkinson's Disease
    Planas-Ballve, Anna
    Pons, Nuria Caballol
    Quiros, Alejandro Peral
    Ruiz, Isabel Gomez
    Marmana, Marta Balague
    Ballester, Alexander J. Velazquez
    Moreno, Dolors Lozano
    Rivera, Asuncion Avila
    BRAIN SCIENCES, 2024, 14 (12)
  • [36] Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study
    Tsuboi, Yoshio
    Koebis, Michinori
    Kogo, Yuki
    Ishida, Takayuki
    Suzuki, Ippei
    Nomoto, Masahiro
    Hattori, Nobutaka
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [37] SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease
    Gomez-Lopez, Ana
    Sanchez-Sanchez, Arantxa
    Natera-Villalba, Elena
    Ros-Castello, Victoria
    Beltran-Corbellini, Alvaro
    Fanjul-Arbos, Samira
    Parees Moreno, Isabel
    Lopez-Sendon Moreno, Jose Luis
    Martinez Castrillo, Juan Carlos
    Alonso-Canovas, Araceli
    BRAIN SCIENCES, 2021, 11 (01) : 1 - 8
  • [38] Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy
    Bovenzi, Roberta
    Liguori, Claudio
    Canesi, Margherita
    D'Amelio, Marco
    De Pandis, Maria Francesca
    Marini, Carmine
    Monge, Alessandra
    Padovani, Alessandro
    Tessitore, Alessandro
    Stefani, Alessandro
    Zappia, Mario
    NEUROLOGICAL SCIENCES, 2024, 45 (02) : 573 - 583
  • [39] Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence
    Bette, Sagari
    Shpiner, Danielle S.
    Singer, Carlos
    Moore, Henry
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1737 - 1745
  • [40] Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study
    Bianchini, Edoardo
    Sforza, Michela
    Rinaldi, Domiziana
    Alborghetti, Marika
    De Carolis, Lanfranco
    Della Gatta, Francesco
    Pontieri, Francesco E.
    NEUROLOGICAL RESEARCH, 2021, 43 (11) : 950 - 954
12345